Biotech M&A: Poseida Therapeutics Acquired By Roche Holdings, Stock Surges Over 200%

Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage company specializing in allogeneic cell therapy and genetic medicines for cancer, autoimmune, and rare diseases, announced today that it has entered into a merger agreement with Roche Holdings, Inc. (OTCMKTS: RHHBY). Under the agreement, Roche will acquire Poseida for $9.00 per share in cash at closing, along with a non-tradeable contingent value right (CVR) providing additional payments of up to $4.00 per share upon achieving specified milestones. The transaction values Poseida at approximately $1.5Bn on a fully diluted basis.

The proposed acquisition will enhance Roche’s capabilities in allogeneic cell therapy, leveraging Poseida’s expertise and technologies. Key opportunities include CAR-T programs developed under the existing strategic collaboration between Poseida and Roche for hematologic malignancies, as well as expanded applications in solid tumors and autoimmune diseases.

“Poseida’s proprietary non-viral technology platform has demonstrated a remarkable ability to create allogeneic, T SCM -rich CAR-T therapies with the potential to improve clinical outcomes and broaden access to this critical class of medicines. This was most recently evidenced by the compelling interim clinical data for P-BCMA-ALLO1 in multiple myeloma patients,” said Kristin Yarema, Ph.D., President and CEO of Poseida Therapeutics. “Our collaboration with Roche on hematologic malignancies has been highly productive, and we are excited to formally join Roche to advance our pipeline and future programs. With Roche’s global expertise in late-stage development and commercialization, we are poised to bring the transformative potential of allo CAR-T therapies to patients worldwide.”

Upon completion of the transaction, Poseida and its employees will integrate into the Roche Group within its Pharmaceuticals Division.